Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Gene targeting and localized delivery of anti-neoplastic agents More
The technology describes the humanization of a murine anti-carcinoma antibody CC49 which has been shown to react with Tumor Associated Glycoprotein 72 (TAG-72), an antigen which is expressed on human breast, ovarian, colorectal, and other carcinomas. More
Methods and assays which may be used to diagnose and follow the progression of cancers associated with c-Met expression More
The present invention describes cytotoxic compounds with an intracellular target that can selectively enter tumor cells through specific receptors on the cell surface. More
This technology describes several antibodies, both polyclonal and monoclonal, to the prolactin receptor. More
These gene chips detect the over-expression of the cancer-related extracellular matrix (ECM) modifier proteins Anakin and Bromodomain 4 (Brd4). More
This technology can be developed into an assay to screen for breast cancer patients who will be responsive to doxorubicin treatment. More
These cell lines can be used to study the role of the PTEN gene in cancer growth and metastasis. More
CSIC has developed a magnetic nanoparticle which contains at least an active ingredient, which can be used for the treatment of cancer. It can be injected intravenously and targeted to the region of interest using an external magnetic field. More
Development of a compact gene signature that detects genome instability in breast cancer cells More
Related Reports
Market Research Reports provided by reports.innovaro.com
Jan 2011 - 4 pages - $500
Mar 2011 - 5 pages - $500
Feb 2008 - $2,500
Dec 2008 - 200 pages - $1,390
Dec 2010 - 34 pages - $5,700
Nov 2010 - 40 pages - $500
Jul 2011 - 36 pages - $3,800
May 2011 - 7 pages - $500
Jul 2011 - 940 pages - $500
Jul 2011 - 271 pages - $500
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Adenocarcinoma
- Breast cancer, other
- Ductal carcinoma in situ
- Invasive ductal breast cancer
- Invasive lobular breast cancer
- Lobular carcinoma in situ
- Paget's Disease
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us